Trastuzumab Deruxtecan (T-DXd)
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
May, 2024
May 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Apr
Trastuzumab Deruxtecan (T-DXd)
May 16, 2024, 09:09 |
Blog
Kohei Shitara: Happy to report biomarkers in DESTINIY GC01 at Nature Medicine
Kohei Shitara, Medical oncologist at National Cancer Center Hospital East, Japan shared a post on X:…
May 14, 2024, 14:59 |
Blog
Annals of Oncology March 2024 issue article of the month
Annals of Oncology shared a post by Annals of Oncology on X/Twitter, adding: ''The article…
Apr 26, 2024, 17:44 |
Drugs
Paolo Tarantino: The agnostic potential of Antibody Drug Conjugates with Roberto Carmagnani Pestana, MD is among the most cited of 2022-2023 on CA - A Cancer Journal for Clinicians
Apr 8, 2024, 03:54 |
Drugs
Paolo Tarantino: Trastuzumab deruxtecan is now FDA approved for ANY treatment-refractory HER2+ solid tumor
Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared…
All:
4
Posts:
1 - 10
OncoInfluencers: Dialogue with Rob Pieters, hosted by Shushan Hovsepyan
10 Most Promising Cancer Drugs Not Yet Approved: Solid Tumors - 2024 edition by OncoDaily
Elie G. Dib: Excited to share the results of the TAPUR study
OncoInfluencers: Dialogue with Fadlo R. Khuri, hosted by Gevorg Tamamyan
Cedars-Sinai is co-chairing a special AACR conference on transforming the field of Bladder Cancer on May 17-20
Facebook
RSS Feed
Twitter
Linkedin
Youtube